Investigation of the Benefit of Using an Autologous Platelet-rich Fibrin Matrix (Obsidian ASG®) for Treatment of Anastomosis During Rectal Surgery (ORSY)
Primary Purpose
Anastomotic Leak Rectum
Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Obsidian ASG
Sponsored by
About this trial
This is an interventional treatment trial for Anastomotic Leak Rectum
Eligibility Criteria
Inclusion Criteria:
The following inclusion criteria will be considered:
- Written informed consent
- Age > 18 years
- Indication for elective oncological rectal resection in the presence of malignant rectal disease and the lower edge of the tumor, measured from the anal verge with the rigid rectoscope, ≤ 14cm
- Use of a circular anastomosis using the "double stapling technique"(6) during creation of the anastomosis
- Expected availability within the maximum 45-day period of study participation
- The use of "golden standard" stapling technology devices; 3 rows endo linear stapler; 2 rows circular stapling devices should be used in an open and laparoscopic approach
Exclusion Criteria:
The following exclusion criteria will be considered:
- Pregnancy, or the non-exclusion of pregnancy (for women of childbearing potential). In the case of menopause having occurred more than 2 years ago or postmenopausal sterilization or surgical sterilization, the authorized physician is free to classify the female study participant as non-pregnant, so that the pregnancy test otherwise required at the beginning of study participation (or during subject screening) may be omitted.
- Risk of pregnancy occurring while taking part in the study in women not meeting at least one of the following criteria: Onset of menopause more than 2 years ago, postmenopausal sterilization, surgical sterilization, a promise to use contraception (with hormones, coil or diaphragm/condom + spermicide), while enrolled in the study) In the case of onset of menopause more than 2 years ago, postmenopausal sterilization or surgical sterilization, the authorized doctor is free to classify the patient in question as infertile. Furthermore, it is at the discretion of the authorized physician to classify the patient in question on the basis of continuous inpatient care in such a way that the occurrence of pregnancy during participation in the study can be ruled out ("continuous determination of the absence of pregnancy"). If one of the above classifications applies, further measures to ensure that a pregnancy does not occur during the patient's participation in the study may not be required.
- Breastfeeding period
- Lack of legal capacity
- Vulnerable persons according to the law
- Comorbidity with the potential for relevant impairment of anastomosis durability (leukemia, cirrhosis of the liver, Child Pugh C, etc.)
- Preoperative anemia with Hb <8g/dL
- Participating in another study
- Patients on Aspirin not able to stop using Aspirin for medical reasons minimum 3 days before taking the blood sampling.
- Patients on Clopidogrel not able to stop using Clopidogrel for medical reasons minimum 7 days before blood sampling.
- Patients on other platelet aggregation inhibitor therapies
- Contraindication for Obsidian ASG®
- Surgical technique of transanal total mesorectal excision (TaTME)
- Application of a circular powered stapler in the course of anastomosis supply with GSTTM technology or a 3 row circular stapler use while creating the study anastomosis
Sites / Locations
- Krankenhaus der Barmherzigen BrûderRecruiting
- Kepler Universitätsklinikum GmbH, Med campus IIIRecruiting
- Landesklinikum WienerneustadtRecruiting
- Krankenhaus der Barmherzigen Brüder WienRecruiting
- UZ Leuven
- University Hospital Aarhus
- Universität AugsburgRecruiting
- Diakonissenkrankenhaus DresdenRecruiting
- Klinikum FürthRecruiting
- Klinikum Nürnberg NordRecruiting
- University MilanoRecruiting
- University Hospital BelgradeRecruiting
- Granada HospitalRecruiting
- Consorci Hospital General Universitari de ValenciaRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
No Intervention
Arm Label
With Obsidian ASG
Without Obsidian ASG
Arm Description
Anastomosis treatment using standard procedure and Obsidian ASG
Anastomosis treatment using standard procedure
Outcomes
Primary Outcome Measures
Anastomosis insufficiency [yes/no]
Anastomosis insufficiency after colorectal surgery with primary anastomosis
Secondary Outcome Measures
Anastomotic insufficiency [0/A/B/C]*
*ISREC, International Study Group of Rectal Cancer - severity grading of anastomotic leakage
Staple suture line bleeding requiring surgical intervention [yes, with surgical intervention / yes, without surgical intervention / no]
Staple suture line bleeding requiring surgical intervention
Postoperative hospital length of stay [days]
Days spent in hospital after undergoing colorectal surgery
Full Information
NCT ID
NCT05174910
First Posted
November 30, 2021
Last Updated
May 11, 2023
Sponsor
Vivostat
Collaborators
Raffeiner GmbH, AF Schimetta GMbH, Rivolution GmbH, European Commission
1. Study Identification
Unique Protocol Identification Number
NCT05174910
Brief Title
Investigation of the Benefit of Using an Autologous Platelet-rich Fibrin Matrix (Obsidian ASG®) for Treatment of Anastomosis During Rectal Surgery
Acronym
ORSY
Official Title
Investigation of the Benefit of Using an Autologous Platelet-rich Fibrin Matrix (Obsidian ASG®) for Treatment of Anastomosis During Rectal Surgery - a Single-blind, Randomized, Multicenter Pilot Study
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 23, 2021 (Actual)
Primary Completion Date
October 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Vivostat
Collaborators
Raffeiner GmbH, AF Schimetta GMbH, Rivolution GmbH, European Commission
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Anastomotic insufficiency remains one of the most significant problems after rectal resection.The complications following anastomotic insufficiency leads to increased morbidity and mortality with subsequent prolongation of hospital stay and higher costs.
This study is an investigation of the benefit of using an autologous platelet-rich fibrin matrix (Obsidian ASG®) for treatment of anastomosis during rectal surgery - a single-blind, randomized, multicenter pilot study with enrollment of 2x220 patients
The main objective of the study is to investigate on an exploratory basis whether the use of Obsidian ASG® during rectal resection reduces the frequency of postoperative anastomotic insufficiency compared to standard anastomotic technique.
The secondary objectives of the study are to investigate on an exploratory basis:
The frequency of anastomotic insufficiency (ISREC Criteria) severity
Staple line bleeding requiring surgical intervention
The duration of postoperative hospitalization are reduced when using Obsidian ASG ® compared with standard anastomotic treatment alone.
are reduced when Obsidian ASG ® is added to the standard of anastomotic treatment compared with standard anastomotic treatment alone.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anastomotic Leak Rectum
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Multicenter, prospective, randomized, single-blind
Masking
Participant
Allocation
Randomized
Enrollment
440 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
With Obsidian ASG
Arm Type
Active Comparator
Arm Description
Anastomosis treatment using standard procedure and Obsidian ASG
Arm Title
Without Obsidian ASG
Arm Type
No Intervention
Arm Description
Anastomosis treatment using standard procedure
Intervention Type
Device
Intervention Name(s)
Obsidian ASG
Intervention Description
Application of an autologous platelet-rich fibrin matrix
Primary Outcome Measure Information:
Title
Anastomosis insufficiency [yes/no]
Description
Anastomosis insufficiency after colorectal surgery with primary anastomosis
Time Frame
45 days
Secondary Outcome Measure Information:
Title
Anastomotic insufficiency [0/A/B/C]*
Description
*ISREC, International Study Group of Rectal Cancer - severity grading of anastomotic leakage
Time Frame
45 days
Title
Staple suture line bleeding requiring surgical intervention [yes, with surgical intervention / yes, without surgical intervention / no]
Description
Staple suture line bleeding requiring surgical intervention
Time Frame
45 days
Title
Postoperative hospital length of stay [days]
Description
Days spent in hospital after undergoing colorectal surgery
Time Frame
45 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
The following inclusion criteria will be considered:
Written informed consent
Age > 18 years
Indication for elective oncological rectal resection in the presence of malignant rectal disease and the lower edge of the tumor, measured from the anal verge with the rigid rectoscope, ≤ 14cm
Use of a circular anastomosis using the "double stapling technique"(6) during creation of the anastomosis
Expected availability within the maximum 45-day period of study participation
The use of "golden standard" stapling technology devices; 3 rows endo linear stapler; 2 rows circular stapling devices should be used in an open and laparoscopic approach
Exclusion Criteria:
The following exclusion criteria will be considered:
Pregnancy, or the non-exclusion of pregnancy (for women of childbearing potential). In the case of menopause having occurred more than 2 years ago or postmenopausal sterilization or surgical sterilization, the authorized physician is free to classify the female study participant as non-pregnant, so that the pregnancy test otherwise required at the beginning of study participation (or during subject screening) may be omitted.
Risk of pregnancy occurring while taking part in the study in women not meeting at least one of the following criteria: Onset of menopause more than 2 years ago, postmenopausal sterilization, surgical sterilization, a promise to use contraception (with hormones, coil or diaphragm/condom + spermicide), while enrolled in the study) In the case of onset of menopause more than 2 years ago, postmenopausal sterilization or surgical sterilization, the authorized doctor is free to classify the patient in question as infertile. Furthermore, it is at the discretion of the authorized physician to classify the patient in question on the basis of continuous inpatient care in such a way that the occurrence of pregnancy during participation in the study can be ruled out ("continuous determination of the absence of pregnancy"). If one of the above classifications applies, further measures to ensure that a pregnancy does not occur during the patient's participation in the study may not be required.
Breastfeeding period
Lack of legal capacity
Vulnerable persons according to the law
Comorbidity with the potential for relevant impairment of anastomosis durability (leukemia, cirrhosis of the liver, Child Pugh C, etc.)
Preoperative anemia with Hb <8g/dL
Participating in another study
Patients on Aspirin not able to stop using Aspirin for medical reasons minimum 3 days before taking the blood sampling.
Patients on Clopidogrel not able to stop using Clopidogrel for medical reasons minimum 7 days before blood sampling.
Patients on other platelet aggregation inhibitor therapies
Contraindication for Obsidian ASG®
Surgical technique of transanal total mesorectal excision (TaTME)
Application of a circular powered stapler in the course of anastomosis supply with GSTTM technology or a 3 row circular stapler use while creating the study anastomosis
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Peter S Nielsen, MSc
Phone
+4561728995
Email
psn@vivostat.com
First Name & Middle Initial & Last Name or Official Title & Degree
Sven Lange, MSc
Phone
+4560108868
Email
sla@vivostat.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andreas Shamiyeh, Prim.Doz.Dr.
Organizational Affiliation
Kepler Universitätsklinikum Gmbh
Official's Role
Principal Investigator
Facility Information:
Facility Name
Krankenhaus der Barmherzigen Brûder
City
Graz
ZIP/Postal Code
8020
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Felex Aigner, Prim.Doz.Dr
Email
felix.aigner@bbgraz.at
Facility Name
Kepler Universitätsklinikum GmbH, Med campus III
City
Linz
ZIP/Postal Code
4021
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andreas Shamiyeh, Prim.Doz.Dr.
Email
Andreas.Shamiyeh@kepleruniklinikum.at
Facility Name
Landesklinikum Wienerneustadt
City
Wiener Neustadt
ZIP/Postal Code
2700
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Friedrich Längle, Prof. Dr.
Email
Friedrich.Laengle@wienerneustadt.lknoe.at
Facility Name
Krankenhaus der Barmherzigen Brüder Wien
City
Wien
ZIP/Postal Code
4041
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Friedrich Hersbst, Prof. Dr.
Email
friedrich.herbst@bbwien.at
Facility Name
UZ Leuven
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andre D'Hoore, Prof. Dr.
Email
andre.dhoore@uzleuven.be
Facility Name
University Hospital Aarhus
City
Aarhus
ZIP/Postal Code
8200
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Leni Iverson, Prof. Dr.
Email
lenive@rm.dk
Facility Name
Universität Augsburg
City
Augsburg
ZIP/Postal Code
86152
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sebastian Wolf, Dr.
Email
sebastian.wolf@uk-augsburg.de
Facility Name
Diakonissenkrankenhaus Dresden
City
Dresden
ZIP/Postal Code
01099
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thorsten Jacobi, Dr. Med.
Email
thorsten.jacobi@diako-dresden.de
Facility Name
Klinikum Fürth
City
Fürth
ZIP/Postal Code
90766
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Katica Krajinovic, Priv.Doz.Dr.
Email
Katica.Krajinovic@klinikum-fuerth.de
Facility Name
Klinikum Nürnberg Nord
City
Nürnberg
ZIP/Postal Code
90419
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mohamed Hanout, Dr. Prof.
Email
mohamed.hanout@klinikum-nuernberg.de
Facility Name
University Milano
City
Milano
ZIP/Postal Code
20122
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Luigi Boni, Prof. Dr.
Email
luigi.boni@unimi.it
Facility Name
University Hospital Belgrade
City
Belgrade
ZIP/Postal Code
11000
Country
Serbia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Miljan Ceranic, Dr.
Email
miljanceranic1972@gmail.com
Facility Name
Granada Hospital
City
Granada
ZIP/Postal Code
18016
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jorge Sanfiel, Dr.
Email
jorgers91@gmail.com
Facility Name
Consorci Hospital General Universitari de Valencia
City
Valencia
ZIP/Postal Code
46016
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Antonio S. Martinez, Dr.
Email
toncla@comv.es
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Investigation of the Benefit of Using an Autologous Platelet-rich Fibrin Matrix (Obsidian ASG®) for Treatment of Anastomosis During Rectal Surgery
We'll reach out to this number within 24 hrs